GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Invex Therapeutics Ltd (ASX:IXC) » Definitions » 5-Day RSI

Invex Therapeutics (ASX:IXC) 5-Day RSI : 70.40 (As of Dec. 14, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Invex Therapeutics 5-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 5-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.

As of today (2024-12-14), Invex Therapeutics's 5-Day RSI is 70.40.

The industry rank for Invex Therapeutics's 5-Day RSI or its related term are showing as below:

ASX:IXC's 5-Day RSI is ranked worse than
91.02% of 1525 companies
in the Biotechnology industry
Industry Median: 40.16 vs ASX:IXC: 70.40

Competitive Comparison of Invex Therapeutics's 5-Day RSI

For the Biotechnology subindustry, Invex Therapeutics's 5-Day RSI, along with its competitors' market caps and 5-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Invex Therapeutics's 5-Day RSI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Invex Therapeutics's 5-Day RSI distribution charts can be found below:

* The bar in red indicates where Invex Therapeutics's 5-Day RSI falls into.



Invex Therapeutics  (ASX:IXC) 5-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Invex Therapeutics  (ASX:IXC) 5-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 5-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.


Invex Therapeutics 5-Day RSI Related Terms

Thank you for viewing the detailed overview of Invex Therapeutics's 5-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


Invex Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
38 Rowland Street, Level 1, Subiaco, WA, AUS, 6008
Invex Therapeutics Ltd is a biopharmaceutical company, focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised ICP including TBI, stroke and hydrocephalus. In addition, the Group has generated early-stage data on the use of Exenatide in the treatment of glaucoma, through the lowering of intraocular pressure in the eye. Geographically, it operates only in Australia.

Invex Therapeutics Headlines

From GuruFocus

Ken Fisher's Top 4th-Quarter Trades

By Graham Griffin Graham Griffin 02-01-2021

Fisher Asset Management Trims Infosys, Equinor Positions

By Tiziano Frateschi Tiziano Frateschi 02-07-2021